COLO B Coloplast A/S Class B

Coloplast A/S - Transactions in connection with share buy-back programme, week 15

Coloplast A/S - Transactions in connection with share buy-back programme, week 15

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 6 – 8 April 2020:

DateNumber of sharesAverage purchase price, DKKTransaction value, DKK
6 April 202015,0001,009.2515,138,750
7 April 202021,000977.7420,532,540
8 April 2020400988.24395,296
Accumulated until now under the programme240,426918.98220,946,042

Henceforth, Coloplast owns 3,292,786 treasury B shares of DKK 1 equal to 1.52% of the company’s total share capital.

An overview showing the transaction data for the period 6 – 8 April 2020 is enclosed.

Kind regards,

Investor Relations

Coloplast A/S

Tel.

 

For further information, please contact

  

Investors and analysts

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. /

Email:

                                                                                       

Press and the media

Lina Danstrup

Sr. Media Relations Manager

Tel. 4911 2607

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Danmark

CVR NR. 69749917

Website

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-04.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments

EN
14/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, ...

Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, 1. halvår 2024/25 Delårsrapport, første halvår 2024/25  1. oktober 2024 – 31. marts 2025  Coloplast leverede 6% organisk vækst i 2. kvartal, påvirket af produkttilbagekaldelsen i Urologi og et svagt kvartal i Stomi. Overskudsgraden1 i 2. kvartal holdt sig stabil på 27%. Den rapporterede omsætning målt i danske kroner steg 5%, påvirket af frasalget af hudplejeforretningen.  Den organiske vækst pr. forretningsområde var 4% i Stomi, 8% i Kontinens, 7% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje og -1% i Urol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch